Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma

A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with... The XP regimen demonstrated a promising antitumor activity in metastatic esophageal squamous cell carcinoma, which may potentially replace the FP regimen. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma

Loading next page...
 
/lp/springer-journals/a-phase-ii-study-of-capecitabine-and-cisplatin-xp-as-first-line-MJqm53D97M

References (21)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Springer-Verlag
Subject
Biomedicine; Oncology ; Pharmacology/Toxicology ; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-007-0577-6
pmid
17762932
Publisher site
See Article on Publisher Site

Abstract

The XP regimen demonstrated a promising antitumor activity in metastatic esophageal squamous cell carcinoma, which may potentially replace the FP regimen.

Journal

Cancer Chemotherapy and PharmacologySpringer Journals

Published: Jun 1, 2008

There are no references for this article.